Christopher Mallow
Overview
Explore the profile of Christopher Mallow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
1802
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Link-Gelles R, Chickery S, Webber A, Ong T, Rowley E, DeSilva M, et al.
MMWR Morb Mortal Wkly Rep
. 2025 Feb;
74(6):73-82.
PMID: 40014628
COVID-19 vaccination averted approximately 68,000 hospitalizations during the 2023-24 respiratory season. In June 2024, CDC and the Advisory Committee on Immunization Practices (ACIP) recommended that all persons aged ≥6 months...
2.
Khan A, Zhu Y, Babcock H, Busse L, Duggal A, Exline M, et al.
Vaccine
. 2025 Jan;
48:126806.
PMID: 39884913
Background: Understanding similarities and differences between hesitancy for influenza and COVID-19 vaccines could facilitate strategies to improve public receptivity toward vaccination. Methods: We compared hesitancy for COVID-19 vaccines during the...
3.
Lewis N, Harker E, Grant L, Zhu Y, Grijalva C, Chappell J, et al.
Clin Infect Dis
. 2024 Nov;
PMID: 39607747
Background: clinical guidelines recommend initiation of antiviral therapy as soon as possible for patients hospitalized with confirmed or suspected influenza. Methods: A multicenter US observational sentinel surveillance network prospectively enrolled...
4.
Lewis N, Harker E, Leis A, Zhu Y, Talbot H, Grijalva C, et al.
Vaccine
. 2024 Nov;
43(Pt 2):126492.
PMID: 39515195
Background: In test-negative studies of vaccine effectiveness (VE), including patients with co-circulating, vaccine-preventable, respiratory pathogens in the control group for the pathogen of interest can introduce a downward bias on...
5.
DeCuir J, Surie D, Zhu Y, Lauring A, Gaglani M, McNeal T, et al.
Influenza Other Respir Viruses
. 2024 Nov;
18(11):e70027.
PMID: 39496339
Background: Assessments of COVID-19 vaccine effectiveness are needed to monitor the protection provided by updated vaccines against severe COVID-19. We evaluated the effectiveness of original monovalent and bivalent (ancestral strain...
6.
Hager D, Zhu Y, Sohn I, Stubblefield W, Streiff M, Gaglani M, et al.
J Infect Dis
. 2024 Oct;
231(2):378-385.
PMID: 39405261
Background: Coronavirus disease 2019 (COVID-19) is a strong risk factor for venous thromboembolism (VTE). Few studies have evaluated the effectiveness of COVID-19 vaccination in preventing hospitalization for COVID-19 with VTE....
7.
Ma K, Surie D, Lauring A, Martin E, Leis A, Papalambros L, et al.
Clin Infect Dis
. 2024 Aug;
PMID: 39107255
Background: Assessing variant-specific COVID-19 vaccine effectiveness (VE) and severity can inform public health risk assessments and decisions about vaccine composition. BA.2.86 and its descendants, including JN.1 (referred to collectively as...
8.
Ma K, Surie D, Lauring A, Martin E, Leis A, Papalambros L, et al.
medRxiv
. 2024 Jun;
PMID: 38883802
Background: Assessing COVID-19 vaccine effectiveness (VE) and severity of SARS-CoV-2 variants can inform public health risk assessments and decisions about vaccine composition. BA.2.86 and its descendants, including JN.1 (referred to...
9.
Surie D, Yuengling K, DeCuir J, Zhu Y, Lauring A, Gaglani M, et al.
JAMA Netw Open
. 2024 Apr;
7(4):e244954.
PMID: 38573635
Importance: On June 21, 2023, the Centers for Disease Control and Prevention recommended the first respiratory syncytial virus (RSV) vaccines for adults aged 60 years and older using shared clinical...
10.
DeCuir J, Payne A, Self W, Rowley E, Dascomb K, DeSilva M, et al.
MMWR Morb Mortal Wkly Rep
. 2024 Feb;
73(8):180-188.
PMID: 38421945
In September 2023, CDC's Advisory Committee on Immunization Practices recommended updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccination for all persons aged ≥6 months to prevent COVID-19, including severe disease. However, few...